By: Sharleen Menezes, Senior Toxicologist
Sharleen Menezes is a Senior Toxicologist (PhD, DABT) in Novotech’s Drug Development Consulting group, advising sponsors on toxicology strategy, nonclinical planning, and FDA-facing development decisions. Her experience across global drug development brings a practical, science-led perspective to evolving regulatory frameworks.
Sweta Kumar, Senior Consultant
Sweta Kumar is a board-certified Senior Toxicologist in Novotech’s Drug Development Consulting group with more than 15 years of experience in nonclinical safety assessment and drug development. She advises sponsors on nonclinical strategy and regulatory planning, with deep expertise in evidence generation for development decisions.
Executive Perspective
The FDA’s draft guidance on New Approach Methodologies (NAMs) moves the discussion from policy intent to regulatory execution. Building on the FDA Modernization Act 2.0 (2022), the Agency has, for the first time, outlined a practical framework for how human-relevant, non-animal data can support regulatory decisions. For the industry, this represents an operational shift rather than a merely conceptual one.
The guidance reframes how NAMs data and evidence is generated and judged:
- From default nonclinical study packages to question-driven evidence generation.
- From animal models as the standard to human relevance as the primary criterion.
Programs designed around specific regulatory questions, and human relevance can become more efficient and predictive. Conversely, programs that adopt NAMs without a clear decision framework risk adding complexity without reducing uncertainty.
What This Changes
1. Animal Studies Are No Longer the Default
The guidance removes the implicit assumption that animal studies are required by default. Instead, the expectation is that each model whether it is animal or NAM, is justified based on its ability to answer a specific regulatory question.
This is not a reduction in rigor of assessment; it is a shift in burden of proof.
Nonclinical implication:
Programs must be designed around decision-critical endpoints (e.g., target-mediated toxicity, human-specific pharmacology, off-target risk), with a clear rationale for why each chosen method for the program is the most informative.
Nonclinical studies, without justification of relevance, will become regulatory liability.
2. Validation Is Context-Specific, Not Universal
The FDA is moving away from the idea that NAMs require broad, cross-indication validation. Instead, acceptability is tied to “context of use.”
Sponsors have greater flexibility for using NAMs approach to address the safety and efficacy of an asset, which is coupled with a higher expectation for a scientific justification of the approach rather the requirement upfront for formal validation of the NAM.
Nonclinical implication:
Sponsors must explicitly define:
- What question the NAM addresses
- Why it is more informative than existing approaches
- How outputs translate into regulatory decisions
Mechanistic models (e.g., hepatotoxicity, immune activation, species-specific biology) are strong candidates, but only when tightly linked to decision-making.
3. Totality of Evidence Becomes the Default Framework
NAMs are not positioned as wholesale replacements for animal studies. Instead, the FDA emphasizes integration across the totality of available nonclinical and clinical evidence.
At this time, NAMs will:
- Replace studies only where they provide equal or superior human relevance
- Complement animal data where translation is uncertain
- Resolve mechanistic ambiguity that in vivo models cannot address
Nonclinical implication:
The focus shifts from individual studies to coherence of the overall evidence package.
Data must align across:
- In vitro / NAM outputs
- In vivo nonclinical data
- Emerging and precedented (as available) clinical understanding
A fragmented dataset, even if scientifically strong, will be difficult to defend without a clear regulatory narrative.
4. A Structured Evaluation Framework—With Higher Expectations
The FDA outlines four pillars as a structured evaluation framework to evaluate NAMs:
- Context of use
- Human biological relevance
- Technical performance
- Fit-for-purpose
These are not new concepts—but they are now explicit regulatory criteria.
Nonclinical implication:
Success depends less on data volume and more on clarity of justification of generated data:
- Is the context of use prospectively defined?
- Are acceptance criteria established?
- Is the link to regulatory decisions explicit?
A well-documented scientific rationale is now as critical as the data itself.
5. Early FDA Engagement Is Risk Control, not a Formality
The guidance strongly reinforces pre-IND engagement, particularly when NAMs are intended to replace or significantly modify traditional approaches.
Nonclinical implication:
Regulatory interaction becomes part of study design:
- Alignment on context of use
- Agreement on interpretation of outputs
- Clarity on impact to IND-enabling requirements
Late-stage justification of NAM strategies is likely to result in rework, additional studies, or review delays. Early alignment is not just about permission; it is about protecting the 30-day IND review clock from avoidable Information Requests (IRs) that arise from uncontextualized NAM data.
Where NAMs Deliver Regulatory Value Today
NAMs are most impactful where human-specific biology drives risk and animal models have known translational limitations. In this case, NAMs can be supportive and decision-making within a regulatory framework.
Key current applications include, proarrhythmia (QT/TdP risk), cholestatic and transporter mediated DILI, immune risk for biologics, transporter-mediated renal tubular injury, phototoxicity liability and local toleration (skin/eye).
In these domains, NAMs can replace or materially reduce reliance on animal studies, provided their role in decision-making is clearly defined and justified.
Where NAMS are Not Yet Sufficient
Despite clear advances, NAMs have limitations in complex, systemic, or low-frequency toxicities, where current models do not fully capture human biology.
Key gaps include, Idiosyncratic or immune-mediated DILI, systemic toxicities, CNS and behavioral endpoints, late-stage reproductive and developmental toxicity, and carcinogenicity.
NAMs should be applied selectively, where they improve confidence, and not where they introduce uncertainty.
Where Sponsors May Face Challenges
Positioning of NAMs within the overall nonclinical and regulatory strategy is key. The main challenges include:
- Applying NAMs in areas where they are not yet decision-making, creating gaps rather than efficiencies
- Generating mechanistic data without linking it to regulatory decisions
- Treating NAMs as direct replacements rather than targeted tools within an integrated evidence framework
- Delaying regulatory alignment on context of use and data interpretation
Poorly defined NAMs strategy may increase complexity without reducing study burden, whereas targeted application can streamline development and improve regulatory confidence.
Case Study Insight: When a NAM-Only Strategy Can Work
A NAM-driven nonclinical package may be viable, but only under well-defined boundary conditions. For example:
- Monoclonal antibody with no pharmacologically relevant animal species
- Target biology is well-characterized with strong clinical precedent
- NAMs addressed binding, selectivity, functional activity, and immune risk
- Safety and PKPD modelling assumptions showed consistency with data generated by comparable molecules
- Human exposure can be reliably predicted using mechanistic modeling approaches (e.g., PBPK)
Critical insight:
This is not a generalizable development model. It represents a specific use case where NAMs can substitute for animal data without reducing regulatory confidence.
Novotech Perspective
The integration of NAMs is fundamentally a nonclinical strategy question with regulatory consequences.
For sponsors, the key decision is not whether to use NAMs, but where do they materially improve confidence in a regulatory decision.
Effective implementation requires:
- Defining decision points upfront (e.g., IND-enabling safety, mechanism, dose selection)
- Identifying where NAMs provide superior or complementary insight
- Ensuring outputs are interpretable within a regulatory framework
- Aligning early with regulators on context of use and expectations
The key filter for any NAM is whether it directly informs a regulatory decision, such as species selection, dose justification, or risk mitigation and not simply whether it generates mechanistic data. The objective is not innovation for its own sake, but provision of regulatory confidence.
Novotech DDC can review your NAM strategy to decision points and regulatory narrative confirming noninferiority with traditional data. We can ensure that your data is well positioned to support regulatory acceptance without introducing complexity, rework or delay.
Forward Outlook
Over the next several years, adoption of NAMs will likely evolve through:
- Indication-specific precedents, where a NAMs is accepted for defined use cases
- Increased regulatory consistency across global regulatory agencies and through industry collaborations
- Greater expectations for integrated evidence packages, rather than standalone datasets
However, full replacement of animal studies, particularly for systemic or multi-organ toxicity—remains unlikely in the near term.
In conclusion
The FDA is not lowering the bar for nonclinical evidence rather, it is changing how the bar is defined.
The key question is no longer whether studies have been completed, but whether the totality of the data and weight-of-evidence is sufficient to support the regulatory decision at hand.
NAMs are now part of that equation—but only when they are clearly justified, fit for purpose and directly tied to decision-making.